| Similar Articles |
|---|
 |
Chemistry World
October 14, 2013
Phillip Broadwith |
5000 jobs to be cut at Teva Israeli generics heavyweight Teva is accelerating its previously announced costcutting drive.   |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance. |
The Motley Fool
November 2, 2010
Eric Dutram |
Tuesday's ETF to Watch: iShares Israel ETF (EIS) TEVA reports earnings. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit. |
The Motley Fool
February 28, 2006
Stephen D. Simpson |
Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances |
Chemistry World
October 5, 2012
Phhillip Broadwith |
Bayer and Evotec team up on endometriosis Bayer Healthcare and Evotec have agreed to collaborate in their search for drugs for endometriosis, a disease in which cells of the type that normally line the uterus wall grow outside of the womb. |
The Motley Fool
August 7, 2007
Brian Lawler |
Nektar Makes a Deal Nektar Therapeutics signs a deal with Bayer AG in an effort to move itself closer to profitability. In return, Bayer gets a co-promotion profit-sharing deal in the U.S., and commercialization rights elsewhere. |
The Motley Fool
May 10, 2006
Stephen D. Simpson |
Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note. |
Chemistry World
November 16, 2012
Andrew Turley |
What lies within Bayer is looking to 'modestly' increase its R&D budget next year -- it was 3 billion euros( 2.4 billion pounds) for 2012 -- and place new emphasis on transferring ideas between research areas within the company. |
The Motley Fool
August 8, 2008
Rich Duprey |
Barr Hits a Home Run Barr gets to market Bayer's authorized generic version of contraceptive Yasmin without fear of competition for at least 180 days -- giving them a huge competitive edge over rivals. |
The Motley Fool
November 8, 2005
Stephen D. Simpson |
Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares? |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
The Motley Fool
July 25, 2005
Stephen D. Simpson |
Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note. |
The Motley Fool
July 18, 2008
Rich Duprey |
More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry. |
The Motley Fool
February 13, 2008
Brian Orelli |
Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted. |
Chemistry World
March 7, 2014
Emma Stoye |
Bayer agrees seed firm takeover in Argentina Agrochemicals giant Bayer CropScience has signed an agreement to acquire Biagro Group, a biological seed treatment producer with headquarters in Argentina. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
The Motley Fool
June 25, 2008
Brian Orelli |
An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets. |
Chemistry World
September 23, 2014
Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months. |
The Motley Fool
June 6, 2005
Stephen D. Simpson |
"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position. |
The Motley Fool
November 26, 2008
Brian Orelli |
Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better." |
Fast Company
November 22, 2011 |
Animal Planet Show Or New York Post Headline? Can you tell which headline appeared in the New York Post or on Animal Planet? |
The Motley Fool
July 28, 2009
Brian Orelli |
All Growth, All the Time This generic-drug maker is no value play. |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
The Motley Fool
June 25, 2009
Brian Orelli |
Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well. |
The Motley Fool
August 28, 2008
Brian Orelli |
Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
March 5, 2008
Brian Orelli |
Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned. |
The Motley Fool
April 7, 2010
Rick Steier |
Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
A More Realistic Bar for Barr Labs An unpleasant, but not altogether unexpected drop makes this generic drug company and better value for investors. |
The Motley Fool
June 30, 2005
Brian Gorman |
Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note. |
Chemistry World
February 16, 2015
Phillip Broadwith |
Teva wins generic esomeprazole race The copycat version will be marketed by Ivax Pharmaceuticals, a subsidiary of Israeli generic behemoth Teva. |
Chemistry World
October 8, 2012
Phillip Broadwith |
Europe gives generics merger the green flag Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. |
Chemistry World
May 9, 2013
Phillip Broadwith |
Carbon nanotubes not commercially viable for Bayer Large-scale commercialization of carbon nanotubes is off the radar at Bayer MaterialScience. The company is shutting down its Baytubes pilot plant. |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
Chemistry World
July 5, 2012 |
Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
IndustryWeek
September 1, 2002
John S. McClenahen |
Bayer's Formula: Two Sites Both Research Triangle Park, N.C., and Kansas City, Mo., are home to newly created Bayer CropScience's North American Operations. |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
The Motley Fool
May 18, 2011
Jordan DiPietro |
Should You Buy and Hold Teva Pharmaceutical? The Israeli pharma firm passes all four of our retirement portfolio tests. |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
BusinessWeek
November 3, 2003
Diane Brady |
Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market. |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most. |
BusinessWeek
October 13, 2003
Gene G. Marcial |
Sontra Medical Looks Healthier with Bayer With giant Bayer as a partner, tiny Sontra Medical could make it big in the $5 billion market for home glucose testing for diabetics. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
Pharmaceutical Executive
October 1, 2011 |
30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies. |
